Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 8.01, 9.01 · 8-K

Translational Development Acquisition Corp.

TDACNASDAQEQUITYCurrent

Other Events

Item 8.01 Other Events. On June 22, 2026, Translational Development Acquisition Corp. (the “Company” or “TDAC”) issued a press release announcing certain results of shareholder redemptions in connection with the shareholder vote held on June 17, 2026 regarding the extension of the deadline by which TDAC must consummate an initial business combination and providing certain information regarding TDA…

Filed Jun 23, 2026Accepted Jun 23, 2026, 10:18 AM EDTCIK 1926599Accession 0001104659-26-076684
Share

Company context

The Company is a blank check company incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an acquisition opportunity in any business, industry, sector, or geographical location, and intends to focus on industries that complement its management team's background, and intends to capitalize on the ability of its management team to identify and acquire a business.

Current securities

Historical securities (1)

Recent company filings

  1. 10-Q filingAug 14, 2026
  2. SCHEDULE 13G - filed by METEORA CAPITAL, LLC regarding Translational Development Acquisition Corp.Aug 14, 2026
  3. SCHEDULE 13G/A - filed by Linden Capital L.P. regarding Translational Development Acquisition Corp.Aug 14, 2026
  4. 425 filingJul 27, 2026
  5. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesJul 27, 2026

Registered securities in this filing

TRANSLATIONAL DEVELOPMENT ACQUISITION CORP. · 8-K · Filed 2026-06-23

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant

Symbol
TDACU
Exchange
NASDAQ
Classification
UNIT
Filing context

Context: From2026-06-222026-06-22_custom_UnitsEachConsistingOfOneClassaOrdinaryShare0.0001ParValueAndOnehalfOfOneRedeemableWarrantMember

Dimensions: us-gaap:StatementClassOfStockAxis

Class A ordinary shares, $0.0001 par value per share

Symbol
TDAC
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: From2026-06-222026-06-22_custom_ClassaOrdinaryShares0.0001ParValuePerShareMember

Dimensions: us-gaap:StatementClassOfStockAxis

Redeemable warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50

Symbol
TDACW
Exchange
NASDAQ
Classification
UNIT
Status
Current
Filing context

Context: From2026-06-222026-06-22_custom_RedeemableWarrantsIncludedAsPartOfUnitsEachWholeWarrantExercisableForOneClassaOrdinaryShareAtExercisePriceOf11.50Member

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000110465926076684 · 3 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. On June 22, 2026, Translational Development Acquisition Corp. (the “Company” or “TDAC”) issued a press release announcing certain results of shareholder redemptions in connection with the shareholder vote held on June 17, 2026 regarding the extension of the deadline by which TDAC must consummate an initial business combination and providing certain information regarding TDAC’s proposed business combination with ProLogium Holding Inc. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information contained in this Current Report on Form 8-K, including Exhibit 99.1, is being filed for purposes of Rule 425 under the Securities Act of 1933, as amended, and Rule 14a-12 under the Securities Exchange Act of 1934, as amended.
Filed exhibits (1)
EX-99.1 (by filename) tm2618552d1_ex99-1.htm

EX-99.1 2 tm2618552d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TDAC Announces Very Successful Share Redemption Results in Connection with Extension Vote 85% of Shares are not Redeemed, resulting in TDAC maintaining $156.8mm in trust 95% of the Shares Voted Were In Favor of the Extension These Great Results Follow the Momentum of the May 27, 2026 announcement of TDAC’s Entry into a Merger Agreement with Prologium ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Prologium is a global leader in next generation lithium ceramic battery technology, moving into growth markets, including AI Data Centers, aerospace, robotics, defense and electric vehicles NEW YORK, NY - June 22,2026 - Translational Development Acquisition Company (NYSE: TDAC) (the “Company” or “TDAC”) announced the very successful results of the shareholder vote held on 6/17/26 regarding the proposed extension of the SPAC life and election of shareholders to redeem their shares or continue to participate in TDAC. In connection with the meeting, holders of the Company’s Class A common stock were given the opportunity to redee…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.